BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

932 related articles for article (PubMed ID: 25622193)

  • 1. Innate immune recognition of cancer.
    Woo SR; Corrales L; Gajewski TF
    Annu Rev Immunol; 2015; 33():445-74. PubMed ID: 25622193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The host STING pathway at the interface of cancer and immunity.
    Corrales L; McWhirter SM; Dubensky TW; Gajewski TF
    J Clin Invest; 2016 Jul; 126(7):2404-11. PubMed ID: 27367184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate immune signaling and regulation in cancer immunotherapy.
    Corrales L; Matson V; Flood B; Spranger S; Gajewski TF
    Cell Res; 2017 Jan; 27(1):96-108. PubMed ID: 27981969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate immune sensing of cancer: clues from an identified role for type I IFNs.
    Gajewski TF; Fuertes MB; Woo SR
    Cancer Immunol Immunother; 2012 Aug; 61(8):1343-7. PubMed ID: 22722449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies.
    Iurescia S; Fioretti D; Rinaldi M
    Front Immunol; 2018; 9():711. PubMed ID: 29686682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
    Woo SR; Fuertes MB; Corrales L; Spranger S; Furdyna MJ; Leung MY; Duggan R; Wang Y; Barber GN; Fitzgerald KA; Alegre ML; Gajewski TF
    Immunity; 2014 Nov; 41(5):830-42. PubMed ID: 25517615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate immune mediators in cancer: between defense and resistance.
    Berraondo P; Minute L; Ajona D; Corrales L; Melero I; Pio R
    Immunol Rev; 2016 Nov; 274(1):290-306. PubMed ID: 27782320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities.
    Massa C; Seliger B
    J Immunol; 2013 Apr; 190(7):3328-37. PubMed ID: 23447683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STING pathway agonism as a cancer therapeutic.
    Flood BA; Higgs EF; Li S; Luke JJ; Gajewski TF
    Immunol Rev; 2019 Jul; 290(1):24-38. PubMed ID: 31355488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity.
    Whitmore MM; DeVeer MJ; Edling A; Oates RK; Simons B; Lindner D; Williams BR
    Cancer Res; 2004 Aug; 64(16):5850-60. PubMed ID: 15313929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STING, DCs and the link between innate and adaptive tumor immunity.
    Vatner RE; Janssen EM
    Mol Immunol; 2019 Jun; 110():13-23. PubMed ID: 29273394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 'kiss of death' by dendritic cells to cancer cells.
    Chan CW; Housseau F
    Cell Death Differ; 2008 Jan; 15(1):58-69. PubMed ID: 17948029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
    Iurescia S; Fioretti D; Rinaldi M
    Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting innate immune pathways in cancer immunotherapy: state of the art.
    Mastellos DC
    J BUON; 2009 Sep; 14 Suppl 1():S123-30. PubMed ID: 19785054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
    Klippstein R; Pozo D
    Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosurveillance and immunotherapy of tumors by innate immune cells.
    Iannello A; Thompson TW; Ardolino M; Marcus A; Raulet DH
    Curr Opin Immunol; 2016 Feb; 38():52-8. PubMed ID: 26686774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.
    Willemen Y; Van den Bergh JM; Lion E; Anguille S; Roelandts VA; Van Acker HH; Heynderickx SD; Stein BM; Peeters M; Figdor CG; Van Tendeloo VF; de Vries IJ; Adema GJ; Berneman ZN; Smits EL
    Cancer Immunol Immunother; 2015 Jul; 64(7):831-42. PubMed ID: 25863943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
    Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
    Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells and damage-associated molecular patterns: endogenous danger signals linking innate and adaptive immunity.
    Nace G; Evankovich J; Eid R; Tsung A
    J Innate Immun; 2012; 4(1):6-15. PubMed ID: 22086146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STING-mediated DNA sensing in cancer immunotherapy.
    Zhou X; Jiang Z
    Sci China Life Sci; 2017 Jun; 60(6):563-574. PubMed ID: 28639100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.